Lenalidomide Tecnigen (Lenalidomide)

Lenalidomide is employed in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow.

• Multiple myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease.
• Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic response in low‑risk patients.
• Mantle cell lymphoma (in combination therapy): enhances overall response rates when used with other antineoplastic agents.

• Lenalidomide binds to the cereblon component of the CRL4^CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This interaction promotes ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to inhibition of malignant cell proliferation, modulation of cytokine production, and enhancement of immune‑mediated tumor cell clearance. The combined anti‑proliferative, immunomodulatory and anti‑angiogenic actions underlie its therapeutic effect.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count leading to infection risk.
• Thrombocytopenia: reduced platelet levels increasing bleeding tendency.
• Anemia: lowered red blood cell count causing fatigue.
• Fatigue: general feeling of tiredness.
• Nausea: upset stomach and possible vomiting.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe rash or Stevens‑Johnson syndrome: skin reactions requiring immediate care.
• Secondary primary malignancies: emergence of new cancers.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating lenalidomide therapy, several safety considerations should be addressed.

• Blood count monitoring: perform baseline and regular CBC to detect cytopenias.
• Thromboembolic risk assessment: evaluate need for prophylactic anticoagulation in high‑risk patients.
• Pregnancy prevention: enforce strict contraception for women of childbearing potential.
• Renal function evaluation: adjust dosing in patients with impaired kidney function.
• Concomitant myelosuppressive therapy: use caution when combined with other agents that lower blood counts.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure.
• Potent P‑glycoprotein inhibitors (e.g., itraconazole): can raise plasma concentrations.
• Combined use with other myelosuppressive drugs: heightens risk of severe cytopenias.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, DOACs): monitor for increased bleeding risk.
• CYP inducers (e.g., rifampin): may reduce drug levels.
• Live attenuated vaccines: consider timing to avoid reduced vaccine efficacy.